Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advanced delivery and therapeutic applications of RNAi [[electronic resource] /] / edited by Kun Cheng, Ram I. Mahato
| Advanced delivery and therapeutic applications of RNAi [[electronic resource] /] / edited by Kun Cheng, Ram I. Mahato |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : John Wiley & Sons Inc., 2013 |
| Descrizione fisica | 1 online resource (535 p.) |
| Disciplina | 572.8/8 |
| Altri autori (Persone) |
ChengKun
MahatoRam I |
| Soggetto topico |
RNA - Therapeutic use
Small interfering RNA - Therapeutic use |
| ISBN |
1-118-61073-3
1-118-61074-1 1-299-46528-5 1-118-61075-X |
| Classificazione | SCI013040 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Advanced Delivery and Therapeutic Applications of RNAi; Contents; Preface; Contributors; About the Editors; Part 1: Introduction and Basics of RNAi; 1 Mechanisms and Barriers to RNAi Delivery; 1.1 Introduction; 1.2 Barriers to Systemic RNAi Delivery; 1.3 Rational Design to Improve RNAi Efficacy; 1.4 Chemical Modifications to Enhance siRNA Stability and Reduce Immune Response; 1.5 Cellular Uptake and Intracellular Release of siRNA; 1.6 Combinatorial Targeting for Targeted RNAi Delivery; 1.7 Cell-Specific Aptamer-Functionalized Nanocarriers for RNAi Delivery
1.8 The Clinical Development and Challenges of siRNAs Therapeutics1.9 Conclusion and Perspectives; References; 2 Analysis of siRNA Delivery Using Various Methodologies; 2.1 Introduction; 2.2 Checkpoints for Analyzing siRNA Delivery; 2.2.1 Circulation Checkpoint; 2.2.2 Organ or Tissue Checkpoint; 2.2.3 Cellular Checkpoint; 2.2.4 RISC Checkpoint; 2.2.5 Target mRNA Knockdown (Indirect Checkpoint); 2.2.6 Protein and Outcome (Indirect Checkpoint); 2.2.7 Safety (Indirect Checkpoint); 2.3 Methods for Analysis of siRNA; 2.3.1 General Considerations; 2.3.2 Hybridization-Based (Non-Imaging) Methods 2.3.3 Non-Hybridization-Based (Non-Imaging) Methods2.3.4 Imaging-Based (Non-Hybridization) Methods; 2.3.5 Imaging-Based (Hybridization) Methods; 2.4 Case Study for siRNA Delivery Analysis; References; 3 Challenges and Opportunities in Bringing RNAi Technologies from Bench to Bed; 3.1 Introduction; 3.2 RNAi Mediator (siRNA or shRNA); 3.2.1 siRNA; 3.2.2 Vector-derived shRNA; 3.2.3 miRNAs; 3.3 Safety Issues of RNAi Mediators; 3.3.1 Immune Stimulation; 3.3.2 RNAi Overexpression; 3.4 Efficacy of RNAi Mediators; 3.4.1 Therapeutic Response; 3.5 RNAi Mediators in Clinical Trials; 3.6 Conclusion References4 Nonclinical Safety Assessments and Clinical Pharmacokinetics for Oligonucleotide Therapeutics: A Regulatory Perspective; 4.1 Introduction; 4.2 Unique Properties of Oligonucleotide-based Therapeutics; 4.3 Regulation of Oligonucleotide-Based Therapeutics; 4.3.1 Submission to the FDA; 4.3.2 Review Process for Non-clinical Studies; 4.3.3 Regulatory Issues; 4.3.4 Clinical Pharmacokinetics; 4.4 Conclusion; Disclaimer; Appendix; References; 5 Role of Promoters and MicroRNA Backbone for Efficient Gene Silencing; 5.1 Introduction; 5.2 Promoters for shRNA Expression 5.2.1 Constitutive Promoters5.2.2 Inducible Promoters; 5.2.3 Site Specific Promoters; 5.3 miRNA-based shRNAs; 5.3.1 miRNA-based shRNA Enhances Gene Silencing; 5.3.2 miRNA-based shRNA Reduces Toxicities; 5.3.3 Application of miRNA-based shRNA for Combination Gene Therapy; 5.4 Concluding Remarks; References; Part 2: RNAi Delivery Strategies; 6 Bioconjugation of siRNA for Site-specific Delivery; 6.1 Introduction; 6.2 Conjugation Strategy; 6.2.1 RNA Chemical Modification; 6.2.2 Site of Conjugation; 6.2.3 Conjugation Chemistry; 6.3 Bioconjugates for Site-specific Delivery 6.3.1 Antibody-siRNA Bioconjugates |
| Record Nr. | UNINA-9910139008603321 |
| Chichester, West Sussex, : John Wiley & Sons Inc., 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advanced delivery and therapeutic applications of RNAi / / edited by Kun Cheng, Ram I. Mahato
| Advanced delivery and therapeutic applications of RNAi / / edited by Kun Cheng, Ram I. Mahato |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : John Wiley & Sons Inc., 2013 |
| Descrizione fisica | 1 online resource (535 p.) |
| Disciplina | 572.8/8 |
| Altri autori (Persone) |
ChengKun
MahatoRam I |
| Soggetto topico |
RNA - Therapeutic use
Small interfering RNA - Therapeutic use |
| ISBN |
1-118-61073-3
1-118-61074-1 1-299-46528-5 1-118-61075-X |
| Classificazione | SCI013040 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Advanced Delivery and Therapeutic Applications of RNAi; Contents; Preface; Contributors; About the Editors; Part 1: Introduction and Basics of RNAi; 1 Mechanisms and Barriers to RNAi Delivery; 1.1 Introduction; 1.2 Barriers to Systemic RNAi Delivery; 1.3 Rational Design to Improve RNAi Efficacy; 1.4 Chemical Modifications to Enhance siRNA Stability and Reduce Immune Response; 1.5 Cellular Uptake and Intracellular Release of siRNA; 1.6 Combinatorial Targeting for Targeted RNAi Delivery; 1.7 Cell-Specific Aptamer-Functionalized Nanocarriers for RNAi Delivery
1.8 The Clinical Development and Challenges of siRNAs Therapeutics1.9 Conclusion and Perspectives; References; 2 Analysis of siRNA Delivery Using Various Methodologies; 2.1 Introduction; 2.2 Checkpoints for Analyzing siRNA Delivery; 2.2.1 Circulation Checkpoint; 2.2.2 Organ or Tissue Checkpoint; 2.2.3 Cellular Checkpoint; 2.2.4 RISC Checkpoint; 2.2.5 Target mRNA Knockdown (Indirect Checkpoint); 2.2.6 Protein and Outcome (Indirect Checkpoint); 2.2.7 Safety (Indirect Checkpoint); 2.3 Methods for Analysis of siRNA; 2.3.1 General Considerations; 2.3.2 Hybridization-Based (Non-Imaging) Methods 2.3.3 Non-Hybridization-Based (Non-Imaging) Methods2.3.4 Imaging-Based (Non-Hybridization) Methods; 2.3.5 Imaging-Based (Hybridization) Methods; 2.4 Case Study for siRNA Delivery Analysis; References; 3 Challenges and Opportunities in Bringing RNAi Technologies from Bench to Bed; 3.1 Introduction; 3.2 RNAi Mediator (siRNA or shRNA); 3.2.1 siRNA; 3.2.2 Vector-derived shRNA; 3.2.3 miRNAs; 3.3 Safety Issues of RNAi Mediators; 3.3.1 Immune Stimulation; 3.3.2 RNAi Overexpression; 3.4 Efficacy of RNAi Mediators; 3.4.1 Therapeutic Response; 3.5 RNAi Mediators in Clinical Trials; 3.6 Conclusion References4 Nonclinical Safety Assessments and Clinical Pharmacokinetics for Oligonucleotide Therapeutics: A Regulatory Perspective; 4.1 Introduction; 4.2 Unique Properties of Oligonucleotide-based Therapeutics; 4.3 Regulation of Oligonucleotide-Based Therapeutics; 4.3.1 Submission to the FDA; 4.3.2 Review Process for Non-clinical Studies; 4.3.3 Regulatory Issues; 4.3.4 Clinical Pharmacokinetics; 4.4 Conclusion; Disclaimer; Appendix; References; 5 Role of Promoters and MicroRNA Backbone for Efficient Gene Silencing; 5.1 Introduction; 5.2 Promoters for shRNA Expression 5.2.1 Constitutive Promoters5.2.2 Inducible Promoters; 5.2.3 Site Specific Promoters; 5.3 miRNA-based shRNAs; 5.3.1 miRNA-based shRNA Enhances Gene Silencing; 5.3.2 miRNA-based shRNA Reduces Toxicities; 5.3.3 Application of miRNA-based shRNA for Combination Gene Therapy; 5.4 Concluding Remarks; References; Part 2: RNAi Delivery Strategies; 6 Bioconjugation of siRNA for Site-specific Delivery; 6.1 Introduction; 6.2 Conjugation Strategy; 6.2.1 RNA Chemical Modification; 6.2.2 Site of Conjugation; 6.2.3 Conjugation Chemistry; 6.3 Bioconjugates for Site-specific Delivery 6.3.1 Antibody-siRNA Bioconjugates |
| Record Nr. | UNINA-9910815366903321 |
| Chichester, West Sussex, : John Wiley & Sons Inc., 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
MicroRNA in regenerative medicine / / edited by Chandan K. Sen
| MicroRNA in regenerative medicine / / edited by Chandan K. Sen |
| Pubbl/distr/stampa | London, England : , : Elsevier, , 2015 |
| Descrizione fisica | 1 online resource (1305 p.) |
| Disciplina | 572.88 |
| Soggetto topico |
RNA
RNA - Therapeutic use Regenerative medicine |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-12-405858-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; MicroRNA inRegenerativeMedicine; Copyright; Dedication; Contents; Contributors; Part 1 - Stem Cells; CHAPTER 1 MicroRNA Biogenesis in Regenerative Medicine; 1.1 INTRODUCTION; 1.2 MACRO IMPACT OF MIRNAS; 1.3 MIRNA BIOGENESIS: DIFFERENT PATHS TO THE SAME DESTINATION; 1.4 MECHANISMS OF MIRNA-INDUCED TRANSLATIONAL REPRESSION; 1.5 MIRNA REGULATION; 1.6 METHODS FOR MIRNA PROFILING; 1.7 BIOINFORMATICS ANALYSIS OF MIRNAS; 1.8 MIRNA APPLICATIONS IN REGENERATIVE MEDICINE; 1.9 MIRNAS AND STEM CELLS; 1.10 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACRONYMS AND ABBREVIATIONS
REFERENCESFURTHER READING; Chapter 2 - Control of Pluripotency and Reprogramming; 2.1 INTRODUCTION; 2.2 BASIC PROPERTIES OF STEM CELLS; 2.3 PLURIPOTENCY; 2.4 NUCLEAR REPROGRAMMING; 2.5 CONCLUSIONS; CHAPTER QUESTIONS; ACRONYMS AND ABBREVIATIONS; REFERENCES; FURTHER READING; Chapter 3 - Epigenetic Modification of MicroRNAs; 3.1 INTRODUCTION; OF A HEALTHY CELL; 3.3 MIRNAS AND EPIGENETIC REGULATION; 3.4 A GENERALIZED MODEL FOR EPIGENETIC REGULATION OF MIRNAS IN DETERMINING CELL FATE; 3.5 EPIGENETIC MODIFICATIONS AND REGENERATIVE MEDICINE; 3.6 EPIGENETIC MODIFYING DRUGS 3.7 THE CLINICAL RELEVANCE OF MIRNAS AND EPIGENETIC MODIFYING DRUGS3.8 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ABBREVIATIONS; REFERENCES; FURTHER READING; Chapter 4 - miRNAs in Bone Marrow-Derived Mesenchymal Stem Cells; 4.1 INTRODUCTION; 4.2 MECHANISMS OF MSC CORRECTION; 4.3 MIRNAS IN GENERAL AND IN WOUND HEALING; 4.4 MSCS IN MIR-146A EXPRESSION: ATTENUATION OF INFLAMMATORY RESPONSE IN DIABETIC WOUNDS; 4.5 CONCLUSIONS AND FUTURE PERSPECTIVES; Chapter Questions; REFERENCES; Chapter 5 - miRNAs in Cancer Stem Cells; 5.1 INTRODUCTION; 5.2 MIRNA REGULATION OF NORMAL STEM CELLS 5.3 MIRNA REGULATION OF CANCER STEM CELLS5.4 REGULATION OF MIRNAS TO INHIBIT CANCER STEM CELLS; 5.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACKNOWLEDGMENTS; REFERENCES; FURTHER READING; Chapter 6 - MicroRNAs in Neural Stem Cells; GLOSSARY; 6.1 INTRODUCTION; 6.2 FIRST INSIGHTS: DICER-KNOCKOUT MICE; 6.3 MIRNA CONTROL OF NSC STATUS AND PROGRESSION ALONG DIFFERENTIATION; 6.4 MIRNAS AS NEURONAL FATE DETERMINANTS; 6.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; REFERENCES; ONLINE RESOURCES; FURTHER READING; Chapter 7 - MicroRNAs in Embryonic Stem Cells; GLOSSARY 7.1 INTRODUCTION7.2 STEM CELLS AND PLURIPOTENCY; 7.3 MIRNAS IN EMBRYONIC STEM CELLS; 7.4 THE ROLE OF MIRNAS IN CELLULAR REPROGRAMMING; 7.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACKNOWLEDGMENTS; REFERENCES; FURTHER READING; Seminal Articles; Reviews; Chapter 8 - MicroRNAs in Normal and Malignant Myelopoiesis; 8.1 INTRODUCTION; 8.2 MIRNAS IN HEMATOPOIETIC STEM CELLS AND LINEAGE-COMMITTED PROGENITOR CELLS; 8.3 CRITICAL TRANSCRIPTION FACTORS CONTROL MIRNAS IN MYELOPOIESIS; 8.4 MIRNA FUNCTIONS IN MATURE MYELOID CELLS; 8.5 MIRNAS IN MALIGNANT MYELOPOIESIS 8.6 ABERRANT MIRNA BIOGENESIS IN AML |
| Record Nr. | UNINA-9910463637603321 |
| London, England : , : Elsevier, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
MicroRNA in regenerative medicine / / edited by Chandan K. Sen
| MicroRNA in regenerative medicine / / edited by Chandan K. Sen |
| Pubbl/distr/stampa | London, England : , : Elsevier, , 2015 |
| Descrizione fisica | 1 online resource (1305 p.) |
| Disciplina | 572.88 |
| Soggetto topico |
RNA
RNA - Therapeutic use Regenerative medicine |
| ISBN | 0-12-405858-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; MicroRNA inRegenerativeMedicine; Copyright; Dedication; Contents; Contributors; Part 1 - Stem Cells; CHAPTER 1 MicroRNA Biogenesis in Regenerative Medicine; 1.1 INTRODUCTION; 1.2 MACRO IMPACT OF MIRNAS; 1.3 MIRNA BIOGENESIS: DIFFERENT PATHS TO THE SAME DESTINATION; 1.4 MECHANISMS OF MIRNA-INDUCED TRANSLATIONAL REPRESSION; 1.5 MIRNA REGULATION; 1.6 METHODS FOR MIRNA PROFILING; 1.7 BIOINFORMATICS ANALYSIS OF MIRNAS; 1.8 MIRNA APPLICATIONS IN REGENERATIVE MEDICINE; 1.9 MIRNAS AND STEM CELLS; 1.10 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACRONYMS AND ABBREVIATIONS
REFERENCESFURTHER READING; Chapter 2 - Control of Pluripotency and Reprogramming; 2.1 INTRODUCTION; 2.2 BASIC PROPERTIES OF STEM CELLS; 2.3 PLURIPOTENCY; 2.4 NUCLEAR REPROGRAMMING; 2.5 CONCLUSIONS; CHAPTER QUESTIONS; ACRONYMS AND ABBREVIATIONS; REFERENCES; FURTHER READING; Chapter 3 - Epigenetic Modification of MicroRNAs; 3.1 INTRODUCTION; OF A HEALTHY CELL; 3.3 MIRNAS AND EPIGENETIC REGULATION; 3.4 A GENERALIZED MODEL FOR EPIGENETIC REGULATION OF MIRNAS IN DETERMINING CELL FATE; 3.5 EPIGENETIC MODIFICATIONS AND REGENERATIVE MEDICINE; 3.6 EPIGENETIC MODIFYING DRUGS 3.7 THE CLINICAL RELEVANCE OF MIRNAS AND EPIGENETIC MODIFYING DRUGS3.8 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ABBREVIATIONS; REFERENCES; FURTHER READING; Chapter 4 - miRNAs in Bone Marrow-Derived Mesenchymal Stem Cells; 4.1 INTRODUCTION; 4.2 MECHANISMS OF MSC CORRECTION; 4.3 MIRNAS IN GENERAL AND IN WOUND HEALING; 4.4 MSCS IN MIR-146A EXPRESSION: ATTENUATION OF INFLAMMATORY RESPONSE IN DIABETIC WOUNDS; 4.5 CONCLUSIONS AND FUTURE PERSPECTIVES; Chapter Questions; REFERENCES; Chapter 5 - miRNAs in Cancer Stem Cells; 5.1 INTRODUCTION; 5.2 MIRNA REGULATION OF NORMAL STEM CELLS 5.3 MIRNA REGULATION OF CANCER STEM CELLS5.4 REGULATION OF MIRNAS TO INHIBIT CANCER STEM CELLS; 5.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACKNOWLEDGMENTS; REFERENCES; FURTHER READING; Chapter 6 - MicroRNAs in Neural Stem Cells; GLOSSARY; 6.1 INTRODUCTION; 6.2 FIRST INSIGHTS: DICER-KNOCKOUT MICE; 6.3 MIRNA CONTROL OF NSC STATUS AND PROGRESSION ALONG DIFFERENTIATION; 6.4 MIRNAS AS NEURONAL FATE DETERMINANTS; 6.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; REFERENCES; ONLINE RESOURCES; FURTHER READING; Chapter 7 - MicroRNAs in Embryonic Stem Cells; GLOSSARY 7.1 INTRODUCTION7.2 STEM CELLS AND PLURIPOTENCY; 7.3 MIRNAS IN EMBRYONIC STEM CELLS; 7.4 THE ROLE OF MIRNAS IN CELLULAR REPROGRAMMING; 7.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACKNOWLEDGMENTS; REFERENCES; FURTHER READING; Seminal Articles; Reviews; Chapter 8 - MicroRNAs in Normal and Malignant Myelopoiesis; 8.1 INTRODUCTION; 8.2 MIRNAS IN HEMATOPOIETIC STEM CELLS AND LINEAGE-COMMITTED PROGENITOR CELLS; 8.3 CRITICAL TRANSCRIPTION FACTORS CONTROL MIRNAS IN MYELOPOIESIS; 8.4 MIRNA FUNCTIONS IN MATURE MYELOID CELLS; 8.5 MIRNAS IN MALIGNANT MYELOPOIESIS 8.6 ABERRANT MIRNA BIOGENESIS IN AML |
| Record Nr. | UNINA-9910787912303321 |
| London, England : , : Elsevier, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
MicroRNA in regenerative medicine / / edited by Chandan K. Sen
| MicroRNA in regenerative medicine / / edited by Chandan K. Sen |
| Pubbl/distr/stampa | London, England : , : Elsevier, , 2015 |
| Descrizione fisica | 1 online resource (1305 p.) |
| Disciplina | 572.88 |
| Soggetto topico |
RNA
RNA - Therapeutic use Regenerative medicine |
| ISBN | 0-12-405858-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; MicroRNA inRegenerativeMedicine; Copyright; Dedication; Contents; Contributors; Part 1 - Stem Cells; CHAPTER 1 MicroRNA Biogenesis in Regenerative Medicine; 1.1 INTRODUCTION; 1.2 MACRO IMPACT OF MIRNAS; 1.3 MIRNA BIOGENESIS: DIFFERENT PATHS TO THE SAME DESTINATION; 1.4 MECHANISMS OF MIRNA-INDUCED TRANSLATIONAL REPRESSION; 1.5 MIRNA REGULATION; 1.6 METHODS FOR MIRNA PROFILING; 1.7 BIOINFORMATICS ANALYSIS OF MIRNAS; 1.8 MIRNA APPLICATIONS IN REGENERATIVE MEDICINE; 1.9 MIRNAS AND STEM CELLS; 1.10 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACRONYMS AND ABBREVIATIONS
REFERENCESFURTHER READING; Chapter 2 - Control of Pluripotency and Reprogramming; 2.1 INTRODUCTION; 2.2 BASIC PROPERTIES OF STEM CELLS; 2.3 PLURIPOTENCY; 2.4 NUCLEAR REPROGRAMMING; 2.5 CONCLUSIONS; CHAPTER QUESTIONS; ACRONYMS AND ABBREVIATIONS; REFERENCES; FURTHER READING; Chapter 3 - Epigenetic Modification of MicroRNAs; 3.1 INTRODUCTION; OF A HEALTHY CELL; 3.3 MIRNAS AND EPIGENETIC REGULATION; 3.4 A GENERALIZED MODEL FOR EPIGENETIC REGULATION OF MIRNAS IN DETERMINING CELL FATE; 3.5 EPIGENETIC MODIFICATIONS AND REGENERATIVE MEDICINE; 3.6 EPIGENETIC MODIFYING DRUGS 3.7 THE CLINICAL RELEVANCE OF MIRNAS AND EPIGENETIC MODIFYING DRUGS3.8 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ABBREVIATIONS; REFERENCES; FURTHER READING; Chapter 4 - miRNAs in Bone Marrow-Derived Mesenchymal Stem Cells; 4.1 INTRODUCTION; 4.2 MECHANISMS OF MSC CORRECTION; 4.3 MIRNAS IN GENERAL AND IN WOUND HEALING; 4.4 MSCS IN MIR-146A EXPRESSION: ATTENUATION OF INFLAMMATORY RESPONSE IN DIABETIC WOUNDS; 4.5 CONCLUSIONS AND FUTURE PERSPECTIVES; Chapter Questions; REFERENCES; Chapter 5 - miRNAs in Cancer Stem Cells; 5.1 INTRODUCTION; 5.2 MIRNA REGULATION OF NORMAL STEM CELLS 5.3 MIRNA REGULATION OF CANCER STEM CELLS5.4 REGULATION OF MIRNAS TO INHIBIT CANCER STEM CELLS; 5.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACKNOWLEDGMENTS; REFERENCES; FURTHER READING; Chapter 6 - MicroRNAs in Neural Stem Cells; GLOSSARY; 6.1 INTRODUCTION; 6.2 FIRST INSIGHTS: DICER-KNOCKOUT MICE; 6.3 MIRNA CONTROL OF NSC STATUS AND PROGRESSION ALONG DIFFERENTIATION; 6.4 MIRNAS AS NEURONAL FATE DETERMINANTS; 6.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; REFERENCES; ONLINE RESOURCES; FURTHER READING; Chapter 7 - MicroRNAs in Embryonic Stem Cells; GLOSSARY 7.1 INTRODUCTION7.2 STEM CELLS AND PLURIPOTENCY; 7.3 MIRNAS IN EMBRYONIC STEM CELLS; 7.4 THE ROLE OF MIRNAS IN CELLULAR REPROGRAMMING; 7.5 CONCLUSIONS AND FUTURE PERSPECTIVES; CHAPTER QUESTIONS; ACKNOWLEDGMENTS; REFERENCES; FURTHER READING; Seminal Articles; Reviews; Chapter 8 - MicroRNAs in Normal and Malignant Myelopoiesis; 8.1 INTRODUCTION; 8.2 MIRNAS IN HEMATOPOIETIC STEM CELLS AND LINEAGE-COMMITTED PROGENITOR CELLS; 8.3 CRITICAL TRANSCRIPTION FACTORS CONTROL MIRNAS IN MYELOPOIESIS; 8.4 MIRNA FUNCTIONS IN MATURE MYELOID CELLS; 8.5 MIRNAS IN MALIGNANT MYELOPOIESIS 8.6 ABERRANT MIRNA BIOGENESIS IN AML |
| Record Nr. | UNINA-9910823632003321 |
| London, England : , : Elsevier, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
